查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088872

醫藥契約製造與研發服務市場：依服務類型、分子類型、劑型及應用分類－2026-2032年全球市場預測

Pharmaceutical Contract Manufacturing & Research Services Market by Service Type, Molecule Type, Dosage Form, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，醫藥契約製造和研發服務市場將成長至 4,440.3 億美元，複合年成長率為 10.92%。

主要市場統計數據
基準年 2025 2148.7億美元
預計年份：2026年 2372億美元
預測年份 2032 4440.3億美元
複合年成長率 (%) 10.92%

執行摘要：藥品契約製造與研究服務

醫藥契約製造和研發服務正從戰術性外包模式轉向策略性營運模式，服務對象包括製藥開發公司、生技公司和專科製藥公司。合約開發和生產組織 (CDMO) 和受託研究機構(CRO) 為藥物發現、臨床前研究、臨床試驗實施、監管申報、原料藥(API) 生產、生技藥品生產、無菌灌裝和包裝、包裝以及上市後生命週期管理提供支援。

醫藥外包產業的變革

生物製藥、高活性原料藥、抗體藥物複合體(ADC)、mRNA 平台、細胞和基因療法以及無菌注射劑正在重塑外包模式。這些領域需要特殊的防護措施、無菌加工、分析表徵、低溫運輸物流和經過驗證的品管體系，從而提升了與合約研發生產機構 (CDMO) 和合約研究機構 (CRO) 合作的戰略價值。

人工智慧對CDMO和CRO營運的累積影響

人工智慧 (AI) 正累積成為提升藥物合約研發和生產整體效率的基礎。在藥物發現和臨床前研究中，AI 驅動的建模支持標靶識別、分子篩檢、毒性預測和方案設計。在臨床開發中，機器學習有助於患者群組識別、最佳化臨床實驗中心選擇、監測臨床實驗風險以及改善分散式臨床實驗。

全球醫藥外包的關鍵區域洞察

亞太地區是領先的醫藥合約生產和研發服務中心，這得益於大規模的患者群體、具有競爭力的營運成本、不斷成長的生物製藥投資，以及中國、印度、日本、韓國、澳洲和東協市場成熟的能力。以美國和加拿大主導的北美地區仍然是世界級創新和外包的中心，擁有創業投資支持的生物技術公司、符合FDA監管的契約製造和先進的臨床試驗網路，滿足了高價值的需求。

關鍵區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在東協，新加坡、馬來西亞、泰國、越南、印尼和菲律賓正在加強其在合約研究、包裝、學名藥生產和區域供應鏈多元化方面的作用，同時擴大在醫療保健領域的投資和監管合作。海灣合作理事會（GCC）優先考慮藥品在地化、生物製藥可及性和國家藥品安全，並透過國家產業戰略、公共採購改革和對本地製造能力的投資來實現這一目標。

各國對醫藥CDMO和CRO策略的關鍵洞察

美國是一個創新主導外包市場，對生物製藥、無菌注射劑、臨床試驗和先進療法的需求強勁，這得益於FDA的監管路徑和強大的生物技術生態系統。加拿大擁有深厚的研究實力、成熟的學術網路和良好的臨床開發環境。墨西哥則憑藉與美國的地理接近性，在包裝、物流和某些製造活動方面享有近岸外包的機會。巴西在拉丁美洲的臨床研究參與、監管現代化和區域藥品需求方面發揮核心作用。

為醫藥外包領域的領導者提供的實用建議

行業領導者應基於韌性、品管成熟度和技術適用性而非最低價格來建立其外包組合。申辦方應評估關鍵原料藥、無菌生產能力和一次性生物製藥原料的二級供應商的合格，並根據ICH Q9和ICH Q10原則，利用基於風險的供應商管治。

調查方法和資料檢驗方法

本執行摘要採用系統的二手資料調查方法編寫，重點關注檢驗的公共領域資訊來源、監管指南、行業資訊披露、監管備案文件和權威的醫療保健資料集。主要資訊來源包括美國食品藥物管理局 (FDA)、歐洲藥品管理局 (EMA)、國際人用藥品註冊技術協調會 (ICH)、世界衛生組織 (WHO)、各國監管機構、臨床試驗註冊中心、同行評審文獻、公開財務報告和權威的製藥業分析報告。

結論：醫藥外包的策略性展望

醫藥契約製造和研發服務正日益成為全球藥物開發價值鏈中不可或缺的一部分。隨著產品平臺日趨複雜，監管要求不斷提高，申辦方越來越需要能夠提供貫穿產品整個生命週期的科學專業知識、合規執行和可擴展生產能力的專家合作夥伴。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 醫藥契約製造與研發服務市場：依服務類型分類

  • 原料藥生產
  • 製藥生產
  • 包裝和整理
  • 發展服務
  • 臨床試驗服務
  • 實驗和測試服務
    • 品管和出貨檢驗
    • 穩定性測試
    • 生物分析和微生物檢測

第8章：製藥契約製造與研發服務市場：依分子類型分類

  • 低分子化合物
  • 生物製劑
  • 先進的治療方法

第9章：藥品契約製造與研發服務市場：按劑型分類

  • 口服固態劑型
  • 口服液體藥物
  • 吸入劑/滴鼻劑
  • 眼科

第10章：醫藥契約製造與研發服務市場：依應用領域分類

  • 腫瘤學
  • 心血管/代謝系統
  • 中樞神經系統
  • 感染疾病
  • 免疫學和炎症
  • 呼吸系統
  • 胃腸病學和肝病學
  • 皮膚科
  • 眼科
  • 罕見疾病和孤兒

第11章 醫藥契約製造與研發服務市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 醫藥契約製造與研發服務市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 藥品契約製造與研發服務市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • AbbVie Inc
  • Almac Group
  • Amanta Healthcare Ltd.
  • Aragen Life Sciences Ltd.
  • Automatic Liquid Packaging Solutions LLC
  • Baxter Pharmaceutical Solutions LLC
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc
  • Curida AS
  • Dalton Pharma Services
  • Evonik Industries AG
  • Famar Group
  • Horizon Pharmaceuticals, Inc
  • Laboratorios SALVAT, SA
  • Lonza Group Ltd.
  • Nephron Pharmaceuticals Corporation
  • Pfizer, Inc.
  • Recipharm AB
  • Rommelag SE & Co. KG
  • Rusoma Laboratories Private Limited
  • Silgan Unicep
  • Unither Pharmaceuticals SAS
  • UPM Pharmaceuticals, Inc.
  • Woodstock Sterile Solutions
Product Code: MRR-AD36CD898497

The Pharmaceutical Contract Manufacturing & Research Services Market is projected to grow by USD 444.03 billion at a CAGR of 10.92% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 214.87 billion
Estimated Year [2026] USD 237.20 billion
Forecast Year [2032] USD 444.03 billion
CAGR (%) 10.92%

Executive Summary: Pharmaceutical Contract Manufacturing & Research Services

Pharmaceutical contract manufacturing and research services are moving from tactical outsourcing to a strategic operating model for drug developers, biotechnology companies, and specialty pharmaceutical firms. Contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) support discovery, preclinical research, clinical trial execution, regulatory submissions, API manufacturing, biologics production, sterile fill-finish, packaging, and post-approval lifecycle management.

Demand is anchored in measurable industry realities: the U.S. FDA Center for Drug Evaluation and Research approved 55 novel drugs in 2023 and 50 in 2024, while biologics, orphan drugs, oncology therapies, and complex modalities continue to increase development and manufacturing intensity. Sponsors are using external partners to access GMP capacity, scientific expertise, digital trial infrastructure, and global regulatory knowledge without carrying the full fixed-cost burden of in-house assets.

Transformative Shifts in the Pharmaceutical Outsourcing Landscape

The outsourcing landscape is being reshaped by biologics, high-potency APIs, antibody-drug conjugates, mRNA platforms, cell and gene therapies, and sterile injectables. These categories require specialized containment, aseptic processing, analytical characterization, cold-chain logistics, and validated quality systems, increasing the strategic value of CDMO and CRO partnerships.

At the same time, sponsors are rebalancing supply chains after pandemic-era disruptions, raw material constraints, and geopolitical trade risks. Nearshoring, dual sourcing, and regional redundancy are becoming standard procurement priorities. Regulatory expectations are also rising through ICH quality guidelines, FDA quality management maturity initiatives, EU GMP requirements, and data integrity enforcement, making proven compliance performance a decisive differentiator for pharmaceutical outsourcing partners.

Cumulative Impact of Artificial Intelligence on CDMO and CRO Operations

Artificial intelligence is becoming a cumulative productivity layer across pharmaceutical contract research and manufacturing. In drug discovery and preclinical research, AI-enabled modeling supports target identification, molecule screening, toxicology prediction, and protocol design. In clinical development, machine learning helps identify patient cohorts, optimize site selection, monitor trial risk, and improve decentralized trial operations.

In manufacturing, AI supports process analytical technology, predictive maintenance, deviation detection, batch-release acceleration, and yield improvement. The greatest impact is expected where AI is deployed within validated GxP frameworks, supported by auditable data lineage, cybersecurity controls, and human scientific oversight. For CDMOs and CROs, AI capability is becoming a commercial advantage rather than a back-office experiment.

Key Regional Insights Across Global Pharmaceutical Outsourcing

Asia-Pacific is a major hub for pharmaceutical contract manufacturing and research services, supported by large patient populations, competitive operating costs, expanding biologics investment, and mature capabilities in China, India, Japan, South Korea, Australia, and ASEAN markets. North America remains a premium innovation and outsourcing center, led by the United States and Canada, where venture-backed biotechnology, FDA-regulated manufacturing, and advanced clinical trial networks support high-value demand.

Europe maintains strength in quality-driven CDMO services, advanced therapies, and regulated clinical research, supported by EMA oversight and deep expertise in Germany, France, Italy, Spain, and the United Kingdom. Latin America, led by Brazil and Mexico, is gaining importance for clinical trial recruitment, regional packaging, and access to treatment-naive patient populations. The Middle East is investing in pharmaceutical localization and health security, while Africa offers long-term potential as regulatory harmonization, vaccine manufacturing investment, and clinical research infrastructure improve.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN is strengthening its role in contract research, packaging, generics manufacturing, and regional supply chain diversification as Singapore, Malaysia, Thailand, Vietnam, Indonesia, and the Philippines expand healthcare investment and regulatory cooperation. The GCC is prioritizing pharmaceutical localization, biologics access, and sovereign medicine security through national industrial strategies, public procurement reforms, and investments in local manufacturing capacity.

The European Union remains a regulatory benchmark for GMP, pharmacovigilance, and clinical research standards, making EU-based CDMOs and CROs attractive for complex programs. BRICS economies are central to API supply, generics scale, patient recruitment, and domestic innovation. G7 countries dominate high-value R&D, advanced therapy commercialization, and regulatory science, while NATO-aligned markets increasingly view pharmaceutical supply resilience, essential medicines availability, and critical input security as strategic priorities.

Key Country Insights for Pharmaceutical CDMO and CRO Strategy

The United States is an innovation-led outsourcing market with strong demand for biologics, sterile injectables, clinical trials, and advanced therapies supported by FDA regulatory pathways and a deep biotechnology ecosystem. Canada offers research depth, established academic networks, and a favorable clinical development environment, while Mexico benefits from proximity to the United States and nearshoring opportunities for packaging, logistics, and selected manufacturing activities. Brazil is Latin America's anchor for clinical research participation, regulatory modernization, and regional pharmaceutical demand.

The United Kingdom, Germany, France, Italy, and Spain remain central to European contract research and GMP manufacturing, with Germany and France particularly strong in high-quality industrial capabilities and regulated production. Russia retains domestic manufacturing needs but faces geopolitical constraints affecting international collaboration and supply chain access. China and India are major engines for API production, generics manufacturing, biologics investment, and clinical research capacity. Japan emphasizes quality, innovation, and regulated development pathways, Australia is valued for early-phase trials and R&D incentives, and South Korea is recognized for biologics CDMO scale, advanced manufacturing infrastructure, and export-oriented pharmaceutical capabilities.

Actionable Recommendations for Pharmaceutical Outsourcing Leaders

Industry leaders should build outsourcing portfolios around resilience, quality maturity, and technical fit rather than lowest unit cost. Sponsors should qualify secondary suppliers for critical APIs, sterile capacity, and single-use biologics inputs while using risk-based vendor governance aligned with ICH Q9 and ICH Q10 principles.

CDMOs and CROs should invest in differentiated capabilities, including high-potency containment, aseptic fill-finish, biologics characterization, decentralized trial platforms, real-world evidence analytics, and AI-enabled quality systems. Commercial teams should emphasize regulatory track record, inspection history, data integrity, on-time delivery, and technology transfer performance. Leaders that combine scientific specialization with flexible capacity and transparent digital collaboration will be best positioned to win long-term strategic partnerships.

Research Methodology and Data Validation Approach

This executive summary is developed using a structured secondary-research methodology focused on verified public-domain sources, regulatory guidance, industry disclosures, regulatory filings, and authoritative healthcare datasets. Core inputs include FDA, EMA, ICH, WHO, national regulatory agencies, clinical trial registries, peer-reviewed literature, public financial reports, and recognized pharmaceutical industry analyses.

The methodology emphasizes triangulation across demand indicators, regulatory developments, manufacturing capacity signals, therapeutic modality trends, and regional policy initiatives. Insights are validated for consistency, relevance, and recency, with preference given to evidence that can be corroborated through multiple reputable sources. The analysis avoids unsupported forecasts and focuses on operational, regulatory, and market dynamics that directly affect pharmaceutical contract manufacturing and research services.

Conclusion: Strategic Outlook for Pharmaceutical Outsourcing

Pharmaceutical contract manufacturing and research services are becoming essential to the global drug development value chain. As product pipelines become more complex and regulatory expectations rise, sponsors increasingly need specialized partners that can deliver scientific expertise, compliant execution, and scalable capacity across the product lifecycle.

The competitive landscape will favor CDMOs and CROs that combine quality excellence, advanced modality capabilities, digital maturity, and regional resilience. Artificial intelligence, strategic supply chain redesign, and expanding global clinical research networks will further redefine outsourcing models. Organizations that act now to strengthen partnerships, diversify supply, and modernize operations will be better positioned to accelerate development timelines and protect long-term value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pharmaceutical Contract Manufacturing & Research Services Market, by Service Type

  • 7.1. Drug Substance Manufacturing
  • 7.2. Drug Product Manufacturing
  • 7.3. Packaging & Finishing
  • 7.4. Development Services
  • 7.5. Clinical Trial Services
  • 7.6. Laboratory & Testing Services
    • 7.6.1. Quality Control & Release Testing
    • 7.6.2. Stability Studies
    • 7.6.3. Bioanalytical & Microbiology Testing

8. Pharmaceutical Contract Manufacturing & Research Services Market, by Molecule Type

  • 8.1. Small Molecules
  • 8.2. Biologics
  • 8.3. Advanced Therapies

9. Pharmaceutical Contract Manufacturing & Research Services Market, by Dosage Form

  • 9.1. Oral Solid
  • 9.2. Oral Liquid
  • 9.3. Inhalation & Nasal
  • 9.4. Ophthalmic

10. Pharmaceutical Contract Manufacturing & Research Services Market, by Application

  • 10.1. Oncology
  • 10.2. Cardiovascular & Metabolic
  • 10.3. Central Nervous System
  • 10.4. Infectious Diseases
  • 10.5. Immunology & Inflammation
  • 10.6. Respiratory
  • 10.7. Gastrointestinal & Hepatology
  • 10.8. Dermatology
  • 10.9. Ophthalmology
  • 10.10. Rare Diseases & Orphan

11. Pharmaceutical Contract Manufacturing & Research Services Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Pharmaceutical Contract Manufacturing & Research Services Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Pharmaceutical Contract Manufacturing & Research Services Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. AbbVie Inc
  • 15.2. Almac Group
  • 15.3. Amanta Healthcare Ltd.
  • 15.4. Aragen Life Sciences Ltd.
  • 15.5. Automatic Liquid Packaging Solutions LLC
  • 15.6. Baxter Pharmaceutical Solutions LLC
  • 15.7. Boehringer Ingelheim International GmbH
  • 15.8. Cambrex Corporation
  • 15.9. Catalent, Inc
  • 15.10. Curida AS
  • 15.11. Dalton Pharma Services
  • 15.12. Evonik Industries AG
  • 15.13. Famar Group
  • 15.14. Horizon Pharmaceuticals, Inc
  • 15.15. Laboratorios SALVAT, S.A
  • 15.16. Lonza Group Ltd.
  • 15.17. Nephron Pharmaceuticals Corporation
  • 15.18. Pfizer, Inc.
  • 15.19. Recipharm AB
  • 15.20. Rommelag SE & Co. KG
  • 15.21. Rusoma Laboratories Private Limited
  • 15.22. Silgan Unicep
  • 15.23. Unither Pharmaceuticals SAS
  • 15.24. UPM Pharmaceuticals, Inc.
  • 15.25. Woodstock Sterile Solutions

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG SUBSTANCE MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUG SUBSTANCE MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG SUBSTANCE MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUG PRODUCT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG PRODUCT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUG PRODUCT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PACKAGING & FINISHING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PACKAGING & FINISHING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PACKAGING & FINISHING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DEVELOPMENT SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CLINICAL TRIAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CLINICAL TRIAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CLINICAL TRIAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LABORATORY & TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LABORATORY & TESTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LABORATORY & TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL QUALITY CONTROL & RELEASE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL QUALITY CONTROL & RELEASE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL QUALITY CONTROL & RELEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL STABILITY STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL STABILITY STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL STABILITY STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOANALYTICAL & MICROBIOLOGY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOANALYTICAL & MICROBIOLOGY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOANALYTICAL & MICROBIOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ADVANCED THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ADVANCED THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ADVANCED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL SOLID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL SOLID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL SOLID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL LIQUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL LIQUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL LIQUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INHALATION & NASAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INHALATION & NASAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INHALATION & NASAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OPHTHALMIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OPHTHALMIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OPHTHALMIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIOVASCULAR & METABOLIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CARDIOVASCULAR & METABOLIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIOVASCULAR & METABOLIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNOLOGY & INFLAMMATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNOLOGY & INFLAMMATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNOLOGY & INFLAMMATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RESPIRATORY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RESPIRATORY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RESPIRATORY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GASTROINTESTINAL & HEPATOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GASTROINTESTINAL & HEPATOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GASTROINTESTINAL & HEPATOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DERMATOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DERMATOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DERMATOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RARE DISEASES & ORPHAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RARE DISEASES & ORPHAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RARE DISEASES & ORPHAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 131. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 133. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 147. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 149. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 151. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 153. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 155. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 157. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 168. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 170. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 174. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 176. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 180. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 182. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 192. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 194. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 198. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 200. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 204. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 206. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 210. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 212. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 216. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 218. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. INDIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 226. INDIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. INDIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 228. INDIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. INDIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 230. INDIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 234. JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 236. JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. AUSTRALIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. AUSTRALIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. AUSTRALIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 240. AUSTRALIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. AUSTRALIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 242. AUSTRALIA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. SOUTH KOREA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 244. SOUTH KOREA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. SOUTH KOREA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 246. SOUTH KOREA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. SOUTH KOREA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 248. SOUTH KOREA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)